Psychedelic Reform Bills Advance in Multiple States as Industry Learns from Cannabis Mistakes

At least three states are simultaneously advancing psychedelic reform legislation in 2026, marking the fastest expansion of psilocybin policy since Oregon became the first state to legalize therapeutic use in 2020.

New Jersey Governor Phil Murphy signed a research framework into law last month, Oregon lawmakers passed sweeping changes to the state's existing psilocybin program, and Alaska activists are collecting signatures for a November ballot measure. The coordinated push represents a dramatic acceleration from just two years ago, when only Oregon and Colorado had operational programs.

But advocates are acutely aware of cannabis legalization's growing pains—particularly the regulatory bottlenecks, equity failures, and market consolidation that plagued early-adopter states. This time, they're trying a different approach.

Learning from Cannabis

The psychedelic reform movement is deliberately avoiding several pitfalls that hampered cannabis rollouts. Oregon's recent legislative overhaul, for instance, streamlined licensing requirements that had created a two-year backlog of applicants. The original program launched in 2023 with only 15 licensed facilitators statewide—a pace that left therapeutic access severely limited.

"We watched what happened in California and Illinois with cannabis," said Melissa Lavasani, a New Jersey-based psychedelic advocate, in testimony before the state legislature. "Regulatory complexity became a barrier to entry that favored deep-pocketed operators over community providers."

New Jersey's research law takes a measured approach, authorizing clinical trials at state universities before establishing a commercial framework. The legislation specifically requires equity provisions be drafted before any therapeutic market opens—a sequencing that cannabis states largely failed to implement.

Alaska's ballot measure, meanwhile, includes automatic expungement language for prior psilocybin-related offenses, addressing criminal justice concerns upfront rather than as an afterthought.

The Numbers

Oregon's psilocybin program generated $2.1 million in tax revenue during its first full year of operation, according to state data. But only 89 facilitators are currently licensed to administer sessions—far below the 300+ projected by initial feasibility studies.

Colorado's program, which launched service centers in late 2024, has licensed 127 facilitators across 14 counties. Yet Denver metro accounts for 78% of those licenses, creating access disparities similar to early cannabis markets.

The New Jersey research framework allocates $5 million in state funding for clinical trials at Rutgers University and Rowan University, focusing specifically on PTSD and treatment-resistant depression. If successful, a therapeutic market could open by 2028.

Industry Crossover

Several cannabis industry veterans are positioning themselves in the psychedelic space, bringing both capital and cautionary tales. Curaleaf founder Boris Jordan recently invested in a Massachusetts-based psilocybin research company. Cresco Labs co-founder Charlie Bachtell joined the board of a Chicago ketamine clinic operator.

But the influx of cannabis money has sparked debate within psychedelic advocacy circles. Some worry that corporate interests will prioritize profit over therapeutic access—the same tension that's defined cannabis policy debates for a decade.

"The cannabis industry taught us that commercialization and medical access don't always align," said Rick Doblin, founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). "We're trying to build frameworks that keep therapeutic outcomes central."

What's Next

Alaska activists need 36,000 valid signatures by July to qualify their measure for the November ballot. Early polling shows 52% support among likely voters—a narrower margin than cannabis legalization enjoyed in 2014.

Oregon's program changes take effect in June, potentially doubling the number of licensed facilitators by year-end. The state is also piloting a reduced-fee licensing track for providers serving low-income communities.

New Jersey's clinical trials are expected to begin enrolling participants in September. If the research phase proceeds smoothly, legislative observers expect a commercial framework bill to be introduced in early 2027.

The federal landscape remains uncertain. While the DEA has granted expanded access for psilocybin research, Schedule I classification still presents barriers that don't exist for cannabis in states with legal markets. Several congressional Democrats have introduced bills to reschedule psilocybin, but none have advanced beyond committee.

For now, the state-by-state approach mirrors cannabis reform's trajectory—with advocates hoping the lessons learned translate to better outcomes.

---

This article is based on original reporting by hightimes.com.